Protego Biopharma closed a $130 million Series B financing to advance its lead oral candidate, PROT‑001, into a pivotal trial for AL (amyloid light‑chain) amyloidosis. The company said the funds will support IND‑enabling work and initiation of a pivotal study targeted for the second half of 2026. PROT‑001 is a small‑molecule kinetic stabilizer designed to bind and stabilize lambda light chains to prevent amyloid formation; Protego framed the approach as a pharmacological‑chaperone strategy that could work alongside existing plasma‑cell targeted therapies. Management described the program as aiming to treat disease at its molecular root rather than only removing pathogenic plasma cells. The financing underscores continued investor appetite for small‑molecule approaches to protein‑misfolding diseases and positions Protego to enter registration‑direction studies for an ultra‑rare indication with high unmet need.